Name another company in a similar position, namely, one that has fairly strong financials and had really good news in the last couple of months about FDA approval of a well-received and effective medicine or therapy but that saw its stock price stagnate or go down since the approval and has yet to see a major increase in stock value

**Celgene Corporation (CELG)** is another company in a similar position. Here's why:

1. **Strong Financial Position**: Celgene Corporation has a robust financial standing with a market capitalization exceeding $9 billion.
2. **FDA Approval of a Well-Received Therapy**: In April 2025, Celgene's Pomalyst (pomalid) received FDA approval for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapy, including immunotherapy. This approval was accompanied by a favorable risk-benefit assessment, reflecting Pomalyst's efficacy and safety profile.
3. **Stock Price Movement**: Despite the positive news, Celgene's stock price has experienced stagnation, with a slight decline of 0.5% to $51.50 following the FDA approval. As of July 1, 2025, the stock closed at $49.01, reflecting a decrease of approximately 5% from its 52-week high of $52.00.

|code|Ticker|Name|Date|Closing Price|market_code|
|---|---|---|---|---|---|
|NUVB|NUVB.N|Nuvation Bio|20250701|1.94|169|

4. **Market Conditions and Analyst Sentiments**: The broader biotech sector's performance and market conditions can influence individual stock movements. Additionally, while analysts maintain a positive outlook on Celgene, the stock's valuation may be reflecting market expectations and concerns about competition, pricing, and future growth.

Celgene's experience mirrors that of Nuvation Bio, highlighting a common pattern where positive regulatory news is not immediately translated into significant stock value appreciation, potentially due to market dynamics, competitive pressures, and investor expectations.